Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes


Description: The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).

Drug: Evacetrapib 130mg daily; Drug: Placebo

Primary Investigator: Kereiakes

Drug/Device Information
Assess Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in patients at High-Risk for Vascular Outcomes
Evacetrapib (LY2484595) is a potent, selective inhibitor of (CETP) leading to increase HDL-C and decrease LDL-C
Randomized 1:1 to Evacetrapib 130 mg daily or placebo
Eli Lilly and Company
Major Inclusion and Exclusion
History of acute coronary syndrome within the last year, TIA, CVA , carotid revascularization or DM with hx of CAD
HDL ≤ 80 mg/dL, triglycerides ≤ 400 mg/dL and LDL no more than 10 mg/dL above target unless on maximum tolerated statin dose (for at least 30 days)
No creatinine >2.2 mg/dL, NYHA class III/IV CHF or cancer (except for nonmelanoma skin cancer) within 3 years
No niacin >250 mg/day